Eli Lilly and : Q4 2021Revised Financial Workbook

Income Statement

LLY
Eli Lilly and Company
Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information*
Investor Relations
Kevin Hern [phone]
Sara Smith [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
Three Months Ended	Three Months Ended	Twelve Months Ended	Twelve Months Ended
($ in millions, except per share data)	December 31, 2021	December 31, 2020	December 31, 2021	December 31, 2020
GAAP Reported	% chng	Adjustments	Non-GAAP Adjusted	% chng	GAAP Reported	Adjustments	Non-GAAP Adjusted	GAAP Reported	% chng	Adjustments	Non-GAAP Adjusted	% chng	GAAP Reported	Adjustments	Non-GAAP Adjusted
Revenue	$7,999.9	8%	-	$7,999.9	8%	$7,440.0	-	$7,440.0	$28,318.4	15%	-	$28,318.4	15%	$24,539.8	-	$24,539.8
Cost of sales	2,050.2	19%	(137.4)	1,912.8	20%	1,719.8	(127.3)	1,592.5	7,312.8	33%	(908.8)	6,404.0	26%	5,483.3	(415.2)	5,068.1
Gross margin	5,949.7	4%	137.4	6,087.1	4%	5,720.2	127.3	5,847.5	21,005.6	10%	908.8	21,914.4	13%	19,056.5	415.2	19,471.7
% of total revenue	74.4%	(2.5) pp	76.1%	(2.5) pp	76.9%	78.6%	74.2%	(3.5) pp	77.4%	(1.9) pp	77.7%	79.3%
Research and development	1,898.3	9%	-	1,898.3	9%	1,744.4	-	1,744.4	6,930.7	16%	-	6,930.7	16%	5,976.3	-	5,976.3
Marketing, selling, and administrative	1,592.0	2%	-	1,592.0	2%	1,553.9	-	1,553.9	6,431.6	5%	-	6,431.6	5%	6,121.2	-	6,121.2
Acquired IPR&D and development milestones †	437.7	(5)%	-	437.7	(5)%	459.9	-	459.9	970.1	26 %	-	970.1	26 %	769.8	-	769.8
Asset impairment, restructuring, and other special charges	104.5	NM	(104.5)	-	- %	(30.1)	30.1	-	316.1	NM	(316.1)	-	- %	131.2	(131.2)	-
Operating income	1,917.2	(4)%	241.9	2,159.1	3 %	1,992.1	97.2	2,089.3	6,357.1	5 %	1,224.9	7,582.0	15 %	6,058.0	546.4	6,604.4
Interest, net	(74.0)	-	(74.0)	(83.4)	-	(83.4)	(314.4)	-	(314.4)	(326.6)	-	(326.6)
Other income	(3.3)	70.6	67.3	560.4	(508.0)	52.4	112.8	227.2	340.0	1,498.5	(1,322.7)	175.8
Other - net, income (expense)	(77.3)	NM	70.6	(6.7)	(78)%	477.0	(508.0)	(31.0)	(201.6)	NM	227.2	25.6	NM	1,171.9	(1,322.7)	(150.8)
Income before income taxes	1,839.9	(25)%	312.5	2,152.4	5 %	2,469.1	(410.8)	2,058.3	6,155.5	(15)%	1,452.1	7,607.6	18 %	7,229.9	(776.3)	6,453.6
Income tax expense	113.8	(68)%	68.1 Joe Alterio: Joe Alterio: $.02 needed to get to $181.9, which agrees to cell R47 on "2021 NOR" tab.	181.9	(32)%	352.3	(85.8)	266.5	573.8	(45)%	300.1 Joe Alterio: Joe Alterio: $.02 needed to get to $873.9, which agrees to cell M47 on "2021 NOR" tab.	Joe Alterio: Joe Alterio: $.02 needed to get to $181.9, which agrees to cell R47 on "2021 NOR" tab.	873.9	3 %	1,036.2	(188.6)	847.6
Effective tax rate	6.2%	(8.1) pp	8.5%	(4.4) pp	14.3%	12.9%	9.3%	(5.0) pp	11.5%	(1.6) pp	14.3%	13.1%
Net income	1,726.1	(18)%	244.4	1,970.5	10 %	2,116.8	(325.0)	1,791.8	5,581.7	(10)%	1,152.0	6,733.7	20 %	6,193.7	(587.7)	5,606.0
Earnings per share	1.90	(18)%	0.27	2.17	10 %	2.32	(0.36)	1.96	6.12	(10)%	1.27 Joe Alterio: Joe Alterio: $.01 adjustment to tie to $7.39 reported on cell M81 of "2021 NOR" tab	7.39	20 %	6.79	(0.65) Joe Alterio: Joe Alterio: Adjusted .01 to arrive at total of $6.14 which matches cell U30 of "Significant Items" tab (and $6.14 also is the correct amount mathematically when taking W38/W42*1000)	6.14
Diluted shares outstanding (thousands)	909,555	- %	-	909,555	- %	912,591	-	912,591	911,681	- %	-	911,681	- %	912,505	-	912,505
* The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and items that are typically highly variable, difficult to predict, and/or of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. For additional information on the adjustments, refer to 'Significant Items'.
† Beginning in 2022, non-GAAP financial measures will not include adjustments for upfront charges and development milestones related to IPR&D projects. Non-GAAP financial measures for the three and twelve months ended December 31, 2021 have been adjusted to reflect this updated presentation.
Note: Numbers may not add due to rounding.
Page 1 of 6 pages of financial data

Significant Items

LLY
Eli Lilly and Company
Significant Items Affecting Net Income
Investor Relations
Kevin Hern [phone]
Sara Smith [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
Significant Items Affecting Net Income
2021	2020
Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Q4	Total
Earnings per share (reported)	$ 1.49	$ 1.53	$ 1.22	$ 1.90	$ 6.12	$ 1.60	$ 1.55	$ 1.33	$ 2.32	$ 6.79
Charge related to repurchase of higher-cost debt	-	-	0.35	-	0.35	-	-	-	-	-
Asset impairment, restructuring and other special charges	0.19	-	-	0.09	0.28	0.06	-	0.11	(0.03)	0.14
Amortization of intangible assets	0.11	0.12	0.12	0.19	0.53	0.05	0.09	0.11	0.11	0.36
COVID-19 antibodies inventory charges	0.07	0.37	(0.11)	(0.07)	0.25	-	-	-	-	-
Net losses (gains) on investments in equity securities	(0.25)	(0.16)	0.19	0.06	(0.16)	(0.14)	(0.44)	(0.13)	(0.44)	(1.15)
Earnings per share (non-GAAP) *	$ 1.61	$ 1.85	$ 1.77	$ 2.17	$ 7.39	$ 1.56	$ 1.20	$ 1.41	$ 1.96	$ 6.14
Acquired IPR&D and Development Milestones †	0.27	0.04	0.17	0.39	0.86	0.05	0.25	-	0.44	0.75
* The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and items that are typically highly variable, difficult to predict, and/or of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. For additional information on the adjustments, refer to 'Significant Items'.
† For informational purposes only -- included in the Earnings per share (reported) and Earnings per share (non-GAAP) amounts above.
Note: Numbers may not add due to rounding.
Page 2 of 6 pages of financial data

2021 Revenue

LLY
Eli Lilly and Company
Product Revenue Report
2021
Investor Relations
Kevin Hern [phone]
Sara Smith [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
2021 Revenue
($ millions)	Q1	Q1	Q1	Q2	Q2	Q2	Q3	Q3	Q3	Q4	Q4	Q4	2021	2021	2021
US	Intl	Total	US	Intl	Total	US	Intl	Total	US	Intl	Total	US	Intl	Total
Baqsimi	20.6	3.8	24.4	22.3	3.6	25.9	27.6	4.3	31.9	25.9	5.1	31.0	96.4	16.8	113.2
Basaglar	175.2	71.4	246.6	133.4	77.3	210.7	114.7	78.1	192.8	165.0	77.4	242.4	588.3	304.2	892.5
Glucagon	20.4	1.4	21.8	7.9	1.5	9.3	8.5	2.0	10.4	6.9	1.9	8.8	43.7	6.7	50.4
Humalog(1)	332.7	284.4	617.0	329.1	278.6	607.6	347.3	279.4	626.7	311.7	290.0	601.7	1,320.7	1,132.3	2,453.0
Humulin	219.0	102.7	321.7	221.1	94.3	315.3	193.4	93.4	286.7	199.4	99.4	298.8	832.9	389.6	1,222.6
Jardiance(2)	151.2	160.8	312.0	194.4	162.1	356.5	221.2	169.2	390.4	240.5	191.4	431.9	807.3	683.5	1,490.8
Trajenta(3)	21.0	73.6	94.6	16.8	72.4	89.2	23.4	72.7	96.1	20.9	71.7	92.6	82.1	290.4	372.5
Trulicity	1,116.8	335.7	1,452.4	1,147.6	388.0	1,535.6	1,201.4	398.8	1,600.1	1,448.6	435.1	1,883.7	4,914.4	1,557.6	6,471.9
Other Diabetes*	4.3	16.1	20.6	7.2	17.9	25.4	5.5	33.2	39.0	16.4	20.2	36.6	33.5	87.7	121.2
Diabetes	2,061.2	1,049.9	3,111.1	2,079.8	1,095.7	3,175.5	2,143.0	1,131.1	3,274.1	2,435.3	1,192.2	3,627.5	8,719.3	4,468.8	13,188.1
Olumiant	24.7	169.1	193.8	17.8	190.6	208.4	194.0	212.9	406.9	87.7	218.3	306.0	324.1	791.0	1,115.1
Qbrexza	10.5	-	10.5	4.7	-	4.7	-	-	-	-	-	-	15.2	-	15.2
Taltz	249.6	153.6	403.2	399.8	169.3	569.1	422.2	170.9	593.1	470.8	176.6	647.4	1,542.4	670.4	2,212.8
Other Immunology*	-	6.4	6.4	0.1	3.2	3.2	-	4.9	4.9	-	3.2	3.2	0.1	17.6	17.6
Immunology	284.8	329.1	613.9	422.4	363.1	785.4	616.2	388.7	1,004.9	558.5	398.1	956.5	1,881.8	1,479.0	3,360.7
Cymbalta	11.0	165.7	176.6	12.4	163.3	175.6	7.0	125.1	132.0	8.4	88.8	97.2	38.7	542.8	581.5
Emgality	101.5	18.0	119.5	112.1	44.2	156.3	99.9	40.1	140.0	121.0	40.4	161.5	434.5	142.7	577.2
Reyvow	2.5	-	2.5	9.4	-	9.4	5.4	(0.2)	5.3	6.4	0.4	6.9	23.8	0.3	24.0
Strattera	6.1	32.6	38.6	7.6	32.9	40.5	2.6	32.5	35.2	1.2	34.9	36.1	17.5	132.8	150.4
Zyprexa	6.9	88.9	95.8	8.4	86.9	95.4	13.0	88.7	101.7	11.3	126.2	137.5	39.6	390.7	430.3
Other Neuroscience*	13.7	18.5	32.4	16.8	18.2	35.0	16.7	19.3	36.0	13.4	18.2	31.4	60.7	74.4	135.0
Neuroscience	141.7	323.7	465.4	166.7	345.5	512.2	144.6	305.5	450.2	161.7	308.9	470.6	614.8	1,283.7	1,898.4
Alimta	261.1	297.8	559.0	353.5	257.1	610.6	297.2	159.8	457.0	322.0	112.8	434.9	1,233.9	827.5	2,061.4
Cyramza	80.2	160.3	240.5	101.4	167.3	268.7	84.8	168.6	253.4	91.9	178.6	270.4	358.1	674.8	1,033.0
Erbitux	107.9	14.4	122.4	135.8	11.2	147.0	114.0	20.3	134.3	124.1	20.5	144.6	481.8	66.4	548.3
Retevmo	16.3	0.5	16.8	22.5	3.2	25.7	29.2	4.4	33.6	31.4	7.2	38.6	99.4	15.4	114.7
Tyvyt	-	109.7	109.7	-	105.0	105.0	-	125.6	125.6	-	77.8	77.8	-	418.1	418.1
Verzenio	172.8	96.2	269.0	209.7	131.6	341.3	199.6	135.9	335.5	252.8	151.3	404.1	834.9	515.0	1,349.9
Other Oncology*	4.2	50.8	54.8	5.4	50.3	55.7	6.1	60.7	66.7	4.9	33.7	38.5	20.7	195.3	215.9
Oncology	642.5	729.7	1,372.2	828.3	725.7	1,554.0	730.9	675.3	1,406.1	827.1	581.9	1,408.9	3,028.8	2,712.5	5,741.3
COVID-19 Antibodies	650.6	159.5	810.1	83.4	65.7	148.9	215.5	1.6	217.1	1,028.5	34.6	1,063.1	1,978.0	261.4	2,239.2
Cialis	8.6	118.1	126.8	(5.2)	286.3	281.0	(6.5)	137.4	130.9	13.6	166.1	179.7	10.6	707.9	718.4
Forteo	97.7	100.8	198.5	122.8	95.6	218.4	109.6	91.3	200.9	111.4	72.6	184.0	441.6	360.3	801.9
Humatrope	32.3	32.6	64.9	(10.2)	32.6	22.4	19.3	31.0	50.2	22.6	28.9	51.4	63.9	125.1	189.0
Other*	21.9	20.8	42.6	16.2	25.8	42.2	17.0	21.4	38.6	17.2	40.7	58.1	72.3	108.8	181.3
Other	811.1	431.8	1,242.9	207.0	506.0	712.9	354.9	282.7	637.7	1,193.3	342.9	1,536.3	2,566.4	1,563.5	4,129.8
TOTAL REVENUE	3,941.3	2,864.3	6,805.6	3,704.2	3,035.9	6,740.1	3,989.6	2,783.3	6,772.8	5,175.9	2,824.0	7,999.9	16,811.0	11,507.4	28,318.4
*Other - Diabetes includes Actos, Competact, Evista, HumaPen, and Lyumjev. Other - Immunology includes Lebrikizumab. Other - Neuro includes Amyvid, Prozac, Symbyax, and Yentreve. Other - Oncology includes Elunate, Gemzar, Halpryza, Portrazza, and Vitrakvi. Other - Other includes Adcirca, Ceclor, Effient, Keflex, Livalo, Zalutia, and other license fee income.
(1) Humalog revenue includes Insulin Lispro
(2) Jardiance revenue includes Glyxambi and Synjardy
(3) Trajenta revenue includes Jentadueto
Note: Numbers may not add due to rounding.
Page 3 of 6 pages of financial data

2021 Revenue Growth

LLY
Eli Lilly and Company
Product Revenue Growth Report
2021
Investor Relations
Kevin Hern [phone]
Sara Smith [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
2021 Revenue Growth
Q1	Q1	Intl	Q1	Q1	Q2	Q2	Intl	Q2	Q2	Q3	Q3	Intl	Q3	Q3	Q4	Q4	Intl	Q4	Q4	2021	2021	Intl	2021	2021
US	Intl	Perform**	Total	Perform**	US	Intl	Perform**	Total	Perform**	US	Intl	Perform**	Total	Perform**	US	Intl	Perform**	Total	Perform**	US	Intl	Perform**	Total	Perform**
Baqsimi	30 %	93 %	85 %	37 %	36 %	NM	42 %	34 %	90 %	89 %	0	62 %	12 %	9 %	53 %	53 %	31 %	26 %	26 %	30 %	30 %	51 %	35 %	32 %	49 %	48 %
Basaglar	(24)%	(3)%	(8)%	(19)%	(20)%	(42)%	27 %	19 %	(27)%	(29)%	(36)%	12 %	10 %	(22)%	(23)%	(19)%	(1)%	- %	(14)%	(14)%	(30)%	8 %	5 %	(21)%	(21)%
Glucagon	(24)%	4 %	- %	(22)%	(22)%	(64)%	37 %	21 %	(59)%	(60)%	(63)%	6 %	(1)%	(58)%	(58)%	(68)%	NM	NM	(60)%	(61)%	(53)%	32 %	23 %	(48)%	(49)%
Humalog(1)	(17)%	(4)%	(9)%	(11)%	(13)%	17 %	2 %	(5)%	9 %	6 %	(11)%	5 %	1 %	(5)%	(6)%	(25)%	(4)%	(4)%	(16)%	(16)%	(11)%	(1)%	(5)%	(7)%	(8)%
Humulin	2 %	1 %	(3)%	2 %	1 %	3 %	(5)%	(12)%	1 %	(1)%	(10)%	2 %	(3)%	(6)%	(8)%	(11)%	(1)%	(2)%	(8)%	(8)%	(4)%	(1)%	(5)%	(3)%	(4)%
Jardiance(2)	5 %	31 %	19 %	17 %	11 %	34 %	39 %	31 %	36 %	33 %	35 %	15 %	21 %	26 %	29 %	43 %	31 %	33 %	38 %	39 %	30 %	28 %	26 %	29 %	28 %
Trajenta(3)	(27)%	14 %	(3)%	1 %	(11)%	2 %	20 %	17 %	16 %	14 %	21 %	1 %	7 %	5 %	10 %	(33)%	9 %	9 %	(4)%	(4)%	(14)%	10 %	7 %	4 %	2 %
Trulicity	20 %	12 %	5 %	18 %	16 %	20 %	40 %	31 %	25 %	23 %	52 %	26 %	23 %	45 %	44 %	25 %	28 %	29 %	25 %	26 %	28 %	26 %	22 %	28 %	27 %
Other Diabetes*	64 %	6 %	3 %	15 %	12 %	NM	27 %	24 %	68 %	65 %	NM	NM	NM	NM	NM	NM	4 %	8 %	81 %	85 %	NM	37 %	37 %	73 %	72 %
Diabetes	4 %	7 %	- %	5 %	2 %	11 %	21 %	13 %	14 %	12 %	19 %	15 %	14 %	18 %	17 %	8 %	13 %	13 %	10 %	10 %	10 %	14 %	10 %	11 %	10 %
Olumiant	NM	32 %	23 %	39 %	31 %	35 %	45 %	37 %	44 %	36 %	NM	44 %	42 %	NM	NM	NM	30 %	32 %	59 %	61 %	NM	38 %	34 %	75 %	71 %
Qbrexza	NM	- %	- %	NM	- %	(5)%	- %	- %	(5)%	(5)%	(100)%	- %	- %	(100)%	(100)%	NM	- %	- %	NM	NM	(24)%	- %	- %	(24)%	(24)%
Taltz	(24)%	32 %	23 %	(9)%	(12)%	38 %	60 %	48 %	44 %	41 %	29 %	33 %	31 %	30 %	30 %	36 %	18 %	20 %	31 %	31 %	20 %	34 %	29 %	24 %	22 %
Other Immunology*	- %	NM	NM	NM	NM	- %	3 %	3 %	3 %	3 %	- %	8 %	8 %	8 %	8 %	- %	(51)%	(51)%	(51)%	(51)%	- %	21 %	21 %	21 %	21 %
Immunology	(16)%	34 %	25 %	5 %	1 %	37 %	51 %	41 %	43 %	39 %	78 %	39 %	37 %	60 %	59 %	48 %	23 %	25 %	37 %	37 %	37 %	36 %	32 %	37 %	35 %
Cymbalta	(5)%	(17)%	(20)%	(16)%	(20)%	60 %	(5)%	(6)%	(2)%	(3)%	(38)%	(29)%	(28)%	(29)%	(28)%	(27)%	(50)%	(49)%	(49)%	(47)%	(8)%	(25)%	(26)%	(24)%	(25)%
Emgality	51 %	NM	NM	61 %	60 %	39 %	NM	NM	79 %	77 %	23 %	NM	NM	53 %	52 %	25 %	NM	NM	47 %	47 %	33 %	NM	NM	59 %	58 %
Reyvow	77 %	NM	NM	77 %	77 %	NM	NM	NM	NM	NM	35 %	NM	NM	31 %	31 %	60 %	23 %	23 %	57 %	57 %	92 %	(31)%	(31)%	89 %	89 %
Strattera	NM	(8)%	(13)%	1 %	(3)%	NM	12 %	7 %	80 %	73 %	11 %	7 %	5 %	8 %	6 %	NM	(1)%	- %	3 %	4 %	NM	2 %	(1)%	17 %	14 %
Zyprexa	(39)%	2 %	(4)%	(3)%	(8)%	(7)%	(1)%	(7)%	(1)%	(7)%	(39)%	(3)%	(5)%	(10)%	(11)%	NM	34 %	36 %	39 %	41 %	(14)%	8 %	5 %	6 %	3 %
Other Neuroscience*	(14)%	(26)%	(26)%	(21)%	(21)%	59 %	(19)%	(22)%	6 %	4 %	(17)%	(16)%	(18)%	(17)%	(18)%	(17)%	(6)%	(5)%	(11)%	(10)%	(4)%	(17)%	(18)%	(12)%	(12)%
Neuroscience	29 %	(8)%	(13)%	- %	(3)%	60 %	8 %	5 %	21 %	19 %	3 %	(7)%	(8)%	(4)%	(5)%	22 %	(10)%	(8)%	(1)%	- %	26 %	(4)%	(6)%	4 %	2 %
Alimta	(19)%	26 %	17 %	- %	(4)%	11 %	16 %	10 %	13 %	11 %	2 %	(44)%	(45)%	(21)%	(21)%	(3)%	(65)%	(64)%	(33)%	(33)%	(2)%	(22)%	(26)%	(12)%	(13)%
Cyramza	(10)%	7 %	3 %	1 %	(2)%	8 %	3 %	2 %	5 %	4 %	(10)%	7 %	8 %	- %	1 %	(12)%	(1)%	4 %	(5)%	(2)%	(6)%	4 %	4 %	- %	- %
Erbitux	(8)%	11 %	10 %	(6)%	(7)%	17 %	(18)%	(17)%	14 %	14 %	(7)%	45 %	48 %	(2)%	(1)%	- %	31 %	35 %	4 %	4 %	- %	18 %	20 %	2 %	2 %
Retevmo	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	69 %	NM	NM	NM	NM	NM	NM	NM	NM	NM
Tyvyt	- %	91 %	79 %	91 %	79 %	- %	64 %	50 %	64 %	50 %	- %	49 %	38 %	49 %	38 %	- %	(24)%	(27)%	(24)%	(27)%	- %	35 %	26 %	35 %	26 %
Verzenio	34 %	64 %	57 %	43 %	41 %	48 %	97 %	91 %	64 %	62 %	26 %	80 %	80 %	43 %	43 %	34 %	62 %	67 %	43 %	45 %	35 %	75 %	74 %	48 %	48 %
Other Oncology	NM	75 %	66 %	NM	100 %	(27)%	(11)%	(17)%	(13)%	(18)%	95 %	85 %	79 %	86 %	80 %	NM	(1)%	(3)%	6 %	5 %	NM	28 %	23 %	33 %	28 %
Oncology	(2)%	34 %	26 %	14 %	11 %	21 %	24 %	18 %	23 %	20 %	7 %	4 %	2 %	5 %	5 %	8 %	(22)%	(21)%	(7)%	(6)%	8 %	7 %	4 %	8 %	7 %
COVID-19 Antibodies	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	21%	62%	63%	22%	22%	NM	NM	NM	NM	NM
Cialis	(67)%	(29)%	(30)%	(34)%	(35)%	NM	NM	NM	NM	NM	NM	(7)%	(9)%	(19)%	(21)%	NM	34 %	34 %	49 %	48 %	(83)%	30 %	28 %	18 %	16 %
Forteo	(20)%	(33)%	(36)%	(27)%	(29)%	3 %	(28)%	(31)%	(14)%	(15)%	(24)%	(25)%	(26)%	(25)%	(25)%	(10)%	(45)%	(43)%	(28)%	(27)%	(13)%	(33)%	(34)%	(23)%	(24)%
Humatrope	(39)%	(9)%	(14)%	(27)%	(29)%	NM	1 %	(3)%	(51)%	(55)%	9 %	(6)%	(6)%	(1)%	(1)%	(69)%	(23)%	(20)%	(54)%	(53)%	(60)%	(10)%	(11)%	(36)%	(37)%
Other*	(17)%	(65)%	(66)%	(50)%	(51)%	(6)%	(24)%	(28)%	(18)%	(20)%	8 %	(30)%	(30)%	(17)%	(17)%	(41)%	(31)%	(29)%	(34)%	(33)%	(18)%	(41)%	(41)%	(33)%	(34)%
Other	NM	5 %	3 %	94 %	93 %	19 %	65 %	61 %	48 %	46 %	84 %	(15)%	(16)%	21 %	20 %	11 %	(8)%	(7)%	6 %	7 %	54 %	10 %	8 %	34 %	33 %
TOTAL REVENUE	18 %	13 %	7 %	16 %	13 %	18 %	29 %	23 %	23 %	20 %	26 %	8 %	7 %	18 %	17 %	13 %	(1)%	1 %	8 %	8 %	18 %	12 %	9 %	15 %	14 %
*Other - Diabetes includes Actos, Competact, Evista, HumaPen, and Lyumjev. Other - Immunology includes Lebrikizumab. Other - Neuro includes Amyvid, Prozac, Symbyax, and Yentreve. Other - Oncology includes Elunate, Gemzar, Halpryza, Portrazza, and Vitrakvi. Other - Other includes Adcirca, Ceclor, Effient, Keflex, Livalo, Zalutia, and other license fee income.
**Performance excludes the impact of foreign exchange rates
(1) Humalog revenue includes Insulin Lispro
(2) Jardiance revenue includes Glyxambi and Synjardy
(3) Trajenta revenue includes Jentadueto
Note: Numbers may not add due to rounding.
Page 4 of 6 pages of financial data

PRV

LLY
Eli Lilly and Company
Effect of Price, Rate, Volume on Revenue
Investor Relations
Kevin Hern [phone]
Sara Smith [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
As Reported ($ millions)	Q1 2021	Q2 2021	Q3 2021	Q4 2021	2021 YTD
$	Price	Rate	Volume	Total	$	Price	Rate	Volume	Total	$	Price	Rate	Volume	Total	$	Price	Rate	Volume	Total	$	Price	Rate	Volume	Total
Region
U.S.	$ 3,941.3	(6 %)	- %	24 %	18 %	$ 3,704.2	(1)%	- %	18 %	18 %	$ 3,989.6	4 %	- %	22 %	26 %	$ 5,175.9	(2)%	- %	14 %	13 %	$ 16,811.0	(1)%	- %	19 %	18 %
Europe	1,321.2	(0 %)	10 %	15 %	24 %	1,209.8	(1)%	11 %	28 %	38 %	1,098.6	(2)%	2 %	5 %	5 %	1,147.3	(3)%	(1)%	0 %	(5)%	4,776.8	(2)%	5 %	11 %	14 %
Japan	571.8	(2 %)	4 %	(6 %)	(3 %)	665.4	(3)%	(2)%	5 %	0 %	595.0	1 %	(4)%	(6)%	(10)%	534.8	(2)%	(6)%	(11)%	(19)%	2,367.0	(2)%	(2)%	(5)%	(8)%
China	362.2	(6 %)	9 %	32 %	35 %	522.5	(19)%	12 %	125 %	118 %	400.3	(23)%	9 %	53 %	38 %	376.5	(30)%	4 %	44 %	17 %	1,661.4	(20)%	8 %	61 %	49 %
ROW	609.1	(2 %)	1 %	2 %	(0 %)	638.1	(2)%	6 %	7 %	11 %	689.4	(3)%	2 %	18 %	18 %	765.5	(3)%	1 %	19 %	17 %	2,702.2	(3)%	2 %	12 %	12 %
Total Revenue	$ 6,805.6	(4 %)	3 %	17 %	16 %	$ 6,740.1	(2)%	3 %	22 %	23 %	$ 6,772.8	0 %	1 %	17 %	18 %	$ 7,999.9	(3)%	0 %	11 %	8 %	$ 28,318.4	(2)%	1 %	16 %	15 %
ROW - OUS excluding Europe, Japan, and China
Note: Numbers may not add due to rounding.
Page 5 of 6 pages of financial data

OID

LLY
Eli Lilly and Company
Other Income/(Deductions)
Investor Relations
Kevin Hern [phone]
Sara Smith [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
2021	2020
As Reported
$ Millions	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Q4	Total
- Interest expense	$ (87.8)	$ (86.9)	$ (83.6)	$ (81.4)	$ (339.8)	$ (92.5)	$ (88.3)	$ (89.6)	$ (89.2)	$ (359.6)
- Interest income	5.5	5.4	7.0	7.4	25.4	14.3	7.1	5.8	5.8	33.0
Interest - net	(82.3)	(81.5)	(76.6)	(74.0)	(314.4)	(78.2)	(81.2)	(83.8)	(83.4)	(326.6)
Other income, net
- FX gain (loss)	(10.6)	(10.8)	(10.9)	(5.4)	(37.8)	(16.7)	(10.3)	(4.8)	(15.4)	(47.2)
- Gain (loss) equity investments	301.5	215.7	(246.8)	(93.5)	176.9	186.6	576.8	141.7	537.1	1,442.2
- Gain (loss) debt extinguishment	-	-	(405.2)	-	(405.2)	-	-	-	-	-
- Miscellaneous income (expense)	39.1	(4.0)	31.0	23.0	89.2	(47.2)	(74.3)	(8.2)	(18.6)	(148.3)
- Retirement Benefit	73.4	71.1	72.6	72.6	289.7	44.6	35.9	114.0	57.3	251.8
Other income (expense)	403.4	272.0	(559.3)	(3.3)	112.8	167.3	528.1	242.7	560.4	1,498.5
Other - net, income (expense)	$ 321.1	$ 190.5	$ (635.9)	$ (77.3)	$ (201.6)	$ 89.1	$ 446.9	$ 158.9	$ 477.0	$ 1,171.9
2021	2020
Non-GAAP*
$ Millions	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Q4	Total
- Interest expense	$ (87.8)	$ (86.9)	$ (83.6)	$ (81.4)	$ (339.8)	$ (92.5)	$ (88.3)	$ (89.6)	$ (89.2)	$ (359.6)
- Interest income	5.5	5.4	7.0	7.4	25.4	14.3	7.1	5.8	5.8	33.0
Interest - net	(82.3)	(81.5)	(76.6)	(74.0)	(314.4)	(78.2)	(81.2)	(83.8)	(83.4)	(326.6)
Other income, net
- FX gain (loss)	(10.6)	(10.8)	(10.9)	(5.4)	(37.8)	(16.7)	(10.3)	(4.8)	(15.4)	(47.2)
- Gain (loss) equity investments	-	-	-	-	-	-	-	-	-	-
- Gain (loss) debt extinguishment	-	-	-	-	-	-	-	-	-	-
- Miscellaneous income (expense)	54.1	26.2	7.6	0.1	88.1	(22.3)	(1.5)	(15.5)	10.5	(28.8)
- Retirement Benefit	73.4	71.1	72.6	72.6	289.7	44.6	35.9	114.0	57.3	251.8
Other income (expense)	116.9	86.5	69.3	67.3	340.0	5.6	24.1	93.7	52.4	175.8
Other - net, income (expense)	$ 34.6	$ 5.0	$ (7.3)	$ (6.7)	$ 25.6	$ (72.6)	$ (57.1)	$ 9.9	$ (31.0)	$ (150.8)
*The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and items that are typically highly variable, difficult to predict, and/or of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.
Note: Numbers may not add due to rounding.
Page 6 of 6 pages of financial data

Proof-Qtrly

LLY
Eli Lilly and Company
Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information*
Three Months Ended	Three Months Ended	Three Months Ended	Three Months Ended
($ in millions, except per share data)	March 31, 2021	March 31, 2020	June 30, 2021	June 30, 2020
GAAP	Non-GAAP	GAAP	Non-GAAP	GAAP	Non-GAAP	GAAP	Non-GAAP
Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted
Revenue	$6,805.6	-	$6,805.6	$5,859.8	-	$5,859.8	$6,740.1	-	$6,740.1	$5,499.4	-	$5,499.4
Cost of sales	1,878.6	(207.2)	1,671.4	1,215.1	(58.6)	1,156.5	1,953.2	(555.2)	1,398.0	1,222.0	(102.8)	1,119.2
Research and development	1,684.8	-	1,684.8	1,392.1	-	1,392.1	1,672.8	-	1,672.8	1,390.2	-	1,390.2
Marketing, selling, and administrative	1,576.0	-	1,576.0	1,549.6	-	1,549.6	1,685.7	-	1,685.7	1,448.6	-	1,448.6
Operating expenses	3,260.8	-	3,260.8	2,941.7	-	2,941.7	3,358.5	-	3,358.5	2,838.8	-	2,838.8
Acquired in-process research and	s/b 0	s/b 0	s/b 0	s/b 0
development	299.3	-	299.3	52.3	-	52.3	25.0	-	25.0	241.8	-	241.8
√	√	√	√
Asset impairment, restructuring,
and other special charges	211.6	(211.6)	-	59.9	(59.9)	-	-	-	-	-	-	-
Other - net, income (expense)	321.1	(286.5)	34.6	89.1	(161.7)	(72.6)	190.5	(185.5)	5.0	446.9	(504.0)	(57.1)
.	.	.	.
Income taxes	121.1	22.1	143.2	223.4	(16.5)	206.9	203.7	76.3	280.0	231.7	(84.5)	147.2
Add: IPRD taxes (from Earnings Release)	62.9	62.9	11.0	11.0	5.3	5.3	14.1	14.1
Sum of above two rows of data	85.0	206.1	(5.5)	217.9	81.6	285.3	(70.4)	161.3
Reported on IR_workbook_Q4_2021	85.0	206.1	(5.5)	217.9	81.6	285.3	(70.4)	161.3
Proof	-	-	-	-	-	-	-	-
√	√	√	√	√	√	√	√
Net income	1,355.3	110.2	1,465.5	1,456.5	(26.7)	1,429.8	1,390.2	293.4	1,683.6	1,412.0	(316.7)	1,095.3
Add: IPRD net income (from Earnings Release)	236.4	236.4	41.3	41.3	19.7	19.7	227.7	227.7
Sum of above two rows of data	346.6	1,701.9	14.6	1,471.1	313.1	1,703.3	(89.0)	1,323.0
Reported on IR_workbook_Q4_2021	346.6	1,701.9	14.6	1,471.1	313.1	1,703.3	(89.0)	1,323.0
Proof	-	-	-	-	-	-	-	-
√	√	√	√	√	√	√	√
Earnings per share	1.49	0.12	1.61	1.60	(0.04)	1.56	1.53	0.32	1.85	1.55	(0.35)	1.20
Add: IPRD EPS (from Earnings Release)	0.26	0.26	0.05	0.05	0.02	0.02	0.25	0.25
Sum of above two rows of data	0.38	1.87	0.01	1.61	0.34	1.87	(0.10)	1.45
Reported on IR_workbook_Q4_2021	0.38	1.87	0.01	1.61	0.34	1.87	(0.10)	1.45
Proof	-	-	-	-	-	-	-	-
√	√	√	√	√	√	√	√
Three Months Ended	Three Months Ended	Three Months Ended	Three Months Ended
September 30, 2021	September 30, 2020	December 31, 2021	December 31, 2020
GAAP	Non-GAAP	GAAP	Non-GAAP	GAAP	Non-GAAP	GAAP	Non-GAAP
Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted
Revenue	$6,772.8	-	$6,772.8	$5,740.6	-	$5,740.6	$7,999.9	-	$7,999.9	$7,440.0	-	$7,440.0
Cost of sales	1,430.8	(9.0)	1,421.8	1,326.4	(126.5)	1,199.9	2,050.2	(137.4)	1,912.8	1,719.8	(127.3)	1,592.5
Research and development	1,708.9	-	1,708.9	1,465.4	-	1,465.4	1,959.4	-	1,959.4	1,838.0	-	1,838.0
Marketing, selling, and administrative	1,577.9	-	1,577.9	1,569.1	-	1,569.1	1,592.0	-	1,592.0	1,553.9	-	1,553.9
Operating expenses	3,286.8	-	3,286.8	3,034.5	-	3,034.5	3,551.4	-	3,551.4	3,391.9	-	3,391.9
Acquired in-process research and	s/b 0	s/b 0	s/b 0	s/b 0
development	174.0	-	174.0	-	-	-	376.6	-	376.6	366.3	-	366.3
√	√	√	√
Asset impairment, restructuring,
and other special charges	-	-	-	101.4	(101.4)	-	104.5	(104.5)	-	(30.1)	30.1	-
Other - net, income (expense)	(635.9)	628.6	(7.3)	158.9	(149.0)	9.9	(77.3)	70.6	(6.7)	477.0	(508.0)	(31.0)
Income taxes	135.2	133.5	268.7	228.8	(1.9)	226.9	113.8	68.1	181.9	352.3	(85.8)	266.5
Add: IPRD taxes (from Earnings Release)	24.5	24.5	-	-	79.3	79.3	50.4	50.4
Sum of above two rows of data	158.0	293.2	(1.9)	226.9	147.4	261.2	(35.4)	316.9
Reported on IR_workbook_Q4_2021	158.0	293.2	(1.9)	226.9	147.4	261.2	(35.4)	316.9
Proof	-	-	-	-	-	-	-	-
√	√	√	√	√	√	√	√
Net income	1,110.1	504.1	1,614.2	1,208.4	80.8	1,289.2	1,726.1	244.4	1,970.5	2,116.8	(325.0)	1,791.8
Add: IPRD net income (from Earnings Release)	149.5	149.5	-	-	297.3	297.3	315.9	315.9
Sum of above two rows of data	653.6	1,763.7	80.8	1,289.2	541.7	2,267.8	(9.1)	2,107.7
Reported on IR_workbook_Q4_2021	653.6	1,763.7	80.8	1,289.2	541.7	2,267.8	(9.1)	2,107.7
Proof	-	-	-	-	-	-	0.0	-
√	√	√	√	√	√	√	√
Earnings per share	1.22	0.56	1.78	1.33	0.09	1.41	1.90	0.26	2.16	2.32	(0.36)	1.96
Add: IPRD EPS (from Earnings Release)	0.16	0.16	-	-	0.33	0.33	0.35	0.35
Sum of above two rows of data	0.72	1.94	0.09	1.41	0.59	2.49	(0.01)	2.31
Reported on IR_workbook_Q4_2021	0.72	1.94	0.09	1.41	0.59	2.49	(0.01)	2.31
Proof	-	-	-	-	-	-	-	-
√	√	√	√	√	√	√	√
*The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and items that are typically highly variable, difficult to predict, and/or of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. For additional information on the adjustments, refer to 'Significant Items'.
Note: Numbers may not add due to rounding.
Page 2 of 12 pages of financial data

Proof-YTD

LLY
Eli Lilly and Company
Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information*
Investor Relations
Kevin Hern [phone]
Sara Smith [phone]
Kento Ueha [phone]
Lauren Zierke [phone]
Three Months Ended	Three Months Ended	Six Months Ended	Six Months Ended
($ in millions, except per share data)	March 31, 2021	March 31, 2020	June 30, 2021	June 30, 2020
GAAP	Non-GAAP	GAAP	Non-GAAP	GAAP	Non-GAAP	GAAP	Non-GAAP
Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted
Revenue	$6,805.6	-	$6,805.6	$5,859.8	-	$5,859.8	$13,545.7	-	$13,545.7	$11,359.2	-	$11,359.2
Cost of sales	1,878.6	(207.2)	1,671.4	1,215.1	(58.6)	1,156.5	3,831.8	(762.4)	3,069.4	2,437.1	(161.4)	2,275.7
Research and development	1,684.8	-	1,684.8	1,392.1	-	1,392.1	3,357.6	-	3,357.6	2,782.3	-	2,782.3
Marketing, selling, and administrative	1,576.0	-	1,576.0	1,549.6	-	1,549.6	3,261.7	-	3,261.7	2,998.2	-	2,998.2
Operating expenses	3,260.8	-	3,260.8	2,941.7	-	2,941.7	6,619.3	-	6,619.3	5,780.5	-	5,780.5
Acquired in-process research and	s/b 0	s/b 0	s/b 0	s/b 0
development	299.3	-	299.3	52.3	-	52.3	324.3	-	324.3	294.1	-	294.1
√	√	√	√
Asset impairment, restructuring,
and other special charges	211.6	(211.6)	-	59.9	(59.9)	-	211.6	(211.6)	-	59.9	(59.9)	-
Other - net, income (expense)	321.1	(286.5)	34.6	89.1	(161.7)	(72.6)	511.6	(472.0)	39.6	536.0	(665.7)	(129.7)
.	.
Income taxes	121.1	22.1	143.2	223.4	(16.5)	206.9	324.8	98.5	423.3	455.1	(101.0)	354.1
Add: IPRD taxes (from Earnings Release)	62.9	62.9	11.0	11.0	68.1	68.1	25.1	25.1
Sum of above two rows of data	85.0	206.1	(5.5)	217.9	166.6	491.4	(75.9)	379.2
Reported on IR_workbook_Q4_2021	85.0	206.1	(5.5)	217.9	166.6	491.4	(75.9)	379.2
Proof	-	-	-	-	-	-	-	-
√	√	√	√	√	√	√	√
Net income	1,355.3	110.2	1,465.5	1,456.5	(26.7)	1,429.8	2,745.5	403.5	3,149.0	2,868.5	(343.4)	2,525.1
Add: IPRD net income (from Earnings Release)	236.4	236.4	41.3	41.3	256.2	256.2	269.0	269.0
Sum of above two rows of data	346.6	1,701.9	14.6	1,471.1	659.7	3,405.2	(74.4)	2,794.1
Reported on IR_workbook_Q4_2021	346.6	1,701.9	14.6	1,471.1	659.7	3,405.2	(74.4)	2,794.1
Proof	-	-	-	-	-	-	-	-
√	√	√	√	√	√	√	√
Earnings per share	1.49	0.12	1.61	1.60	(0.04)	1.56	3.01	0.45	3.46	3.15	(0.38)	2.77
Add: IPRD EPS (from Earnings Release)	0.26	0.26	0.05	0.05	0.28	0.28	0.30	0.30
Sum of above two rows of data	0.38	1.87	0.01	1.61	0.73	3.74	(0.08)	3.07
Reported on IR_workbook_Q4_2021	0.38	1.87	0.01	1.61	0.73	3.74	(0.08)	3.07
Proof	-	-	-	-	-	-	-	-
√	√	√	√	√	√	√	√
Nine Months Ended	Nine Months Ended	Twelve Months Ended	Twelve Months Ended
September 30, 2021	September 30, 2020	December 31, 2021	December 31, 2020
GAAP	Non-GAAP	GAAP	Non-GAAP	GAAP	Non-GAAP	GAAP	Non-GAAP
Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted	Reported	Adjustments	Adjusted
Revenue	$20,318.5	-	$20,318.5	$17,099.8	-	$17,099.8	$28,318.4	-	$28,318.4	$24,539.8	-	$24,539.8
Cost of sales	5,262.6	(771.4)	4,491.2	3,763.5	(287.9)	3,475.6	7,312.8	(908.8)	6,404.0	5,483.3	(415.2)	5,068.1
Research and development	5,066.5	-	5,066.5	4,247.7	-	4,247.7	7,025.9	-	7,025.9	6,085.7	-	6,085.7
Marketing, selling, and administrative	4,839.6	-	4,839.6	4,567.3	-	4,567.3	6,431.6	-	6,431.6	6,121.2	-	6,121.2
Operating expenses	9,906.1	-	9,906.1	8,815.0	-	8,815.0	13,457.5	-	13,457.5	12,206.9	-	12,206.9
Acquired in-process research and	s/b 0	s/b 0	s/b 0	s/b 0
development	498.3	-	498.3	294.1	-	294.1	874.9	-	874.9	660.4	-	660.4
√	√	√	√
Asset impairment, restructuring,
and other special charges	211.6	(211.6)	-	161.3	(161.3)	-	316.1	(316.1)	-	131.2	(131.2)	-
Other - net, income (expense)	(124.3)	156.6	32.3	694.9	(814.7)	(119.8)	(201.6)	227.2	25.6	1,171.9	(1,322.7)	(150.8)
Income taxes	460.0	232.0	692.0	683.9	(102.8)	581.1	573.8	300.1	873.9	1,036.2	(188.7)	847.5
Add: IPRD taxes (from Earnings Release)	92.6	92.6	25.0	25.0	171.9	171.9	75.5	75.5
Sum of above two rows of data	324.6	784.6	(77.8)	606.1	472.0	1,045.8	(113.2)	923.0
Reported on IR_workbook_Q4_2021	324.6	784.6	(77.8)	606.1	472.0	1,045.8	(113.2)	923.0
Proof	-	-	-	-	-	-	-	-
Net income	3,855.6	907.6	4,763.2	4,076.9	(262.7)	3,814.2	5,581.7	1,152.0	6,733.7	6,193.7	(587.6)	5,606.1
Add: IPRD net income (from Earnings Release)	405.7	405.7	269.1	269.1	703.0	703.0	584.9	584.9
Sum of above two rows of data	1,313.3	5,168.9	6.4	4,083.3	1,855.0	7,436.7	(2.7)	6,191.0
Reported on IR_workbook_Q4_2021	1,313.3	5,168.9	6.4	4,083.3	1,855.0	7,436.7	(2.7)	6,191.0
Proof	-	-	(0.0)	-	-	-	0.0	-
Earnings per share	4.23	1.00	5.23 Joe Alterio: Joe Alterio: Increased by $0.01 since the otherwise calculated $5.22 would result in a $0.02 difference when adding the individual quarters across on the Significant Items and QTR Recon tabs ($1.61 +$1.85 +$1.78)	4.47	(0.29)	4.18	6.12	1.27	7.39	6.79	(0.65)	6.14
Add: IPRD EPS (from Earnings Release)	0.45	0.45	0.30	0.30	0.77	0.77	0.64	0.64
Sum of above two rows of data	1.45	5.68	0.01	4.48	2.04	8.16	(0.01)	6.78
Reported on IR_workbook_Q4_2021	1.44	5.67	0.01	4.48	2.04	8.16	(0.01)	6.78
Proof	(0.01)	(0.01)	-	-	-	-	-	-
Note: Numbers may not add due to rounding.

.99